The price of FEMY is predicted to go up -53.13%, based on the high correlation periods with CYCC. The similarity of these two price pattern on the periods is 98.68%.
FEMY
CYCC
Down: -53.13%Similarity: 98.68%
FEMY Revenue Forecast
FEMY EPS Forecast
FEMY FAQs
What is bull’s view on FEMY?
FEMY stock has a bullish outlook due to its recent strategic advancements. The stock is currently supported by strong catalysts, including FDA clearance for FemChec and a new U.S. patent for FemaSeed, which enhances its market potential and intellectual property. Analysts have reiterated a "Strong Buy" rating with a price target of $12, indicating significant upside from current levels.
What is bear's view on FEMY?
FEMY stock is currently trading at $1.15, showing a bearish trend with a recent decline of 0.84% in regular market hours and 2.54% in post-market trading. The bearish view stems from weak momentum indicators, with RSI at 56.83 and MACD near zero, suggesting limited upward strength. Additionally, the stock faces resistance at $1.22 and lacks immediate catalysts to break out of its consolidation range.
What is FEMY revenue forecast for next quarter?
The market consensus for FEMY's revenue in the upcoming quarter is projected to be approximately $1.376M USD.
Chardan analyst Keay Nakae lowered the firm's price target on Femasys to $8 from $10 and keeps a Buy rating on the shares post the Q3 report. The lowered target reflects a higher projected future share count as modeled future capital raises, including one in Q1 of 2025, are expected to be more dilutive due to the current share price, the analyst tells investors in a research note.